A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

Conditions

Phase I

Phase 1a/1b

What is the purpose of this trial?

The purpose of this study is to determine the safety, preliminary evidence of clinical activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents that may improve the therapeutic efficacy of anti-PD-1 monotherapy.

  • Trial with
    Incyte Corporation
  • Start Date
    02/11/2019
  • End Date
    08/30/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Stephanie Rosini

  • Last Updated
    02/13/2019
  • Study HIC
    #2000023802